Published in final edited form as:

Chem Commun (Camb). 2011 January 7; 47(1): 529–531. doi:10.1039/c0cc02253e.

Identification of Dihydropyridines That Reduce Cellular Tau Levels

Christopher G. Evans^a, Umesh K. Jinwal^b, Leah N. Makley^a, Chad A. Dickey^b, and Jason E. Gestwicki^a

^a Department of Pathology and the Life Sciences Institute, University of Michigan, 210 Washtenaw Ave., Ann Arbor, MI 48109 U.S.A.

^b Department of Molecular Medicine, University of South Florida, 4001 E. Fletcher Ave., MDC 36, Tampa, FL 33613, U.S.A.

Abstract

A series of dihydropyridines were identified that have an effect on the accumulation of tau, an important target in Alzheimer's disease. The dihydropyridine collection was expanded using the Hantzsch multicomponent reaction to develop preliminary structure-activity relationships.

Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD).¹ These diseases are collectively termed tauopathies and they are characterized by aggregation of hyperphosphorylated tau. The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other tauopathies.² Therefore, selectively reducing its levels might be an effective therapeutic strategy.

Efforts towards that goal have largely focused on either inhibitors of tau aggregation,³ inhibitors of its phosphorylation⁴ or compounds that stimulate its degradation.⁵ Each of these strategies are potentially promising and well supported by genetic evidence, but many of the compounds identified to date have relatively modest activity. For example, methylene blue (MB), which both inhibits tau aggregation³ and stimulates its degradation through heat shock protein 70 (Hsp70),⁵ has an EC₅₀ value of approximately 10 μM. Other promising compounds, such as the Hsp90 inhibitors 17-AAG and EC1012, reduce tau levels but they also produce a robust stress response, which is expected to diminish their long-term efficacy.^{5,6} Thus, new compounds that counteract tau accumulation are still of interest.

While conducting cell-based screens for small molecules that impact tau levels, we identified the 1,4-dihydropyridine **4a** (data not shown). Based on this finding, we sought to synthesize a focused collection to facilitate characterization of structure-activity relationships (SAR). Accordingly, we were attracted to the Hantzsch multicomponent reaction because of its high atom economy and suitability for combinatorial synthesis. This reaction produces the dihydropyridine core scaffold from an aldehyde, amine, and two 1,3-dicarbonyls in a single step (Scheme 1). Also, it has good functional group tolerance and there are known stereoselective routes.⁷

Correspondence to: Chad A. Dickey; Jason E. Gestwicki.

Tel: 813-396-0639; cddickey@health.usf.edu Fax: 734-764-1247; Tel: 734-615-9537; gestwick@umich.edu.

† Electronic Supplementary Information (ESI) available: Synthesis and characterization of compounds. See DOI: 10.1039/b000000x/

To generate a dihydropyridine collection, we first explored a series of aldehydes that were functionalized with ether bulky aromatics or smaller, alkyl groups (Scheme 1). To maintain the general structure of the initial compound, dimedone **1** (1.5 equiv), ethylacetoacetate **2** (1 equiv), and Yb(OTf)₃ (10 mol%) were mixed in acetonitrile. After stirring for 10 minutes, the aldehyde (1.0 equiv) and ammonium acetate (1.0 equiv) were added. The reactions then proceeded for 3-5 hours, after which they were poured into saturated NaCl, washed with ethylacetate and the products were re-crystallized from 1:3 water:ethanol. Using this approach, compounds **4a-r** were obtained in moderate to good yields (ranging from 69-94%).

To expand the diversity in this collection, we took advantage of published methods⁸ to exchange the ester for a thioester on compounds **4a** and **4b**. Briefly, these examples were refluxed in toluene with 2.2 equivalents of Lawesson's reagent for 1 hr. The resulting products, **5a** and **5b**, were filtered through Celite and purified as above in good yield (Scheme 2).

To test whether modifications to the heterocyclic amine could be tolerated, we combined dimedone with aryl or alkyl amines in acetonitrile to form the enamine.⁹ After 30 minutes, ethylacetoacetate (1.0 eq), 2,4-dichloro benzaldehyde **3a** (1.0 eq) and 10% Yb(OTf)₃ were added and the reaction was allowed to proceed for an additional 4-5 hours. This procedure generated compounds **7a-d** with yields ranging from 71-82% (Scheme 3).

To further diversify the scaffold, we next varied the identity of the 1,3-dicarbonyls (**8** and **9**; Scheme 4). Specifically, we used indanedione and 2,4-pentanedione in place of dimedone to produce derivatives **10a** and **10b** in good yields. On the other side of the molecule, we substituted either methylacetoacetate or benzylacetoacetate for ethylacetoacetate to produce **10c** and **10d** in 82 and 85% yield, respectively.

Finally, to fully exploit the strengths of the Hantzsch reaction we varied multiple components simultaneously. Using the reaction conditions and starting materials employed earlier, we made derivatives **11a-11k** (Scheme 5). These compounds include examples, such as **11b** and **11c**, which contain β -ketoamides. Together, these efforts produced a library of 39 functionalized dihydropyridines. At this stage, no attempt to separate the enantiomers was attempted.

With this collection in hand, we treated cultured IMR32 neuroblastoma cells for 24 hrs with 100 μ M compound and measured endogenous tau levels by Western blot. Some of the compounds, such as **11b-f**, were found to be toxic under these conditions and these were excluded from further analysis. We then compared the remaining examples to the benchmark compounds MB and 17-AAG, which reduced tau levels by approximately 50 to 70% (Figure 1).^{5,6} Based on those values, we imposed an arbitrary threshold of 25% to focus on the most active compounds in the dihydropyridine collection. This analysis focused attention on compounds **4p**, **11a** and **11g**, which reduced tau levels by at least 25%. Interestingly, we also identified examples, such as **4a-b**, **4d**, **10b-c**, **11j** and **11k**, which *increased* tau levels by at least 25%. Previous efforts have also noted compounds that either increase or decrease tau levels and both sets of molecules have been useful probes of tau biology.^{5a-b}

An analysis of these results suggested some preliminary SAR. Specifically, large substitutions on the aldehyde, such as naphthyl (**4j**) or *p*-diphenyl (**4o**) were not tolerated. Likewise, conversion of the ester to a thioester in **5a** and **5b** reduced activity, as did any modification of the heterocyclic amine (compounds **7a-d**). Modest substitutions of an ethyl to methyl group in the diketone (*e.g.* from **4a** to **10c**) had marginal effects but larger groups, such as the benzyl ester in **10d**, abolished activity. Interestingly, minimally functionalized

benzyls in the aldehyde position, such as **4a**, **4b** and **4d**, produced the most potent stimulators of tau accumulation, while smaller alkyl groups, such as in **4p**, tended to produce compounds that reduced tau levels. This finding suggests a way of converting a compound from one that causes tau accumulation to one that leads to tau reductions. However, the impact of modifications at the aldehyde position also seemed to be influenced by the identity of the 1,3-diketone. For example, if dimedone was used, compounds **4a** and **4b** promoted tau accumulation, but replacing it for a methyl diketone, as in **11a** and **11g**, produced relatively strong inhibitors. Together, these findings reveal patterns of substitution that result in compounds that promote either tau degradation or accumulation.

Following this initial screening, we selected compound **11g** for more in-depth studies. In dose dependence experiments, we found that this compound reduced tau levels by ~70% with an IC₅₀ of 7.0 ± 1.5 μ M (Figure 1B), a potency comparable to some of the best, known anti-tau compounds.⁵ To test whether **11g** activates a cellular stress response, we examined the levels of stress-inducible Hsp70 by Western blots and found that Hsp70 levels were not significantly increased, suggesting that **11g** does not act through the stress response (Figure 1B). Next, we generated the two enantiomers of **11g** (**11gS** and **11gR**), using a recently reported, organocatalytic procedure.^{7a} In the IMR32 cells, only **11gS** had activity, with a significantly improved IC₅₀ value of ~ 600 nM (Figure 1C). The cellular target of these dihydropyridines is currently unclear, but the relatively potent activity of **11gS** suggests that further studies are warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

C.G.E. was supported by the NIH Cellular Biotechnology Training Program (GM008353). We also acknowledge financial support from the Abe and Irene Pollin CBD Fund, the Alzheimer's Association (IRG-09-130689), NIH (NS059690 and AG031291) and NSF (MCB-0844512).

Notes and references

1. a Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Trends Neurosci. 2009; 32:150. [PubMed: 19162340] b Jeganathan S, von Bergen M, Mandelkow EM, Mandelkow E. Biochemistry. 2008; 47:10526. [PubMed: 18783251] c Wolfe MS. J Biol Chem. 2009; 284:6021. [PubMed: 18948254]
2. Braak H, Braak E. Acta Neuropathol. 1991; 82:239. [PubMed: 1759558]
3. a Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. J Biol Chem. 2005; 280:7614. [PubMed: 15611092] b Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Proc Natl Acad Sci U S A. 1996; 93:11213. [PubMed: 8855335]
4. Mazanetz MP, Fischer PM. Nat Rev Drug Discov. 2007; 6:464. [PubMed: 17541419]
5. a Koren J 3rd, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, Anderson LJ, Dickey CA. J Cell Mol Med. 2009; 13:619. [PubMed: 19449461] b Jinwal UK, Miyata Y, Koren J 3rd, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA. J Neurosci. 2009; 29:12079. [PubMed: 19793966] c Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. J Neurosci. 2008; 28:12163. [PubMed: 19020010]
6. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr. Hutton M, Burrows F, Petrucelli L. J Clin Invest. 2007; 117:648. [PubMed: 17304350]

7. a Evans CG, Gestwicki JE. *Org Lett*. 2009; 11:2957. [PubMed: 19527003] b Legeay JC, Goujon JY, Vanden Eynde JJ, Toupet L, Bazureau JP. *J Comb Chem*. 2006; 8:829. [PubMed: 17096571] c Maurya AM, Kumar RA. *Tetrahedron*. 2007; 63:1946.
8. Vigante BA, Ozols YY, Chekavichus BS, Dubur GY. *Khimiya Geterotsiklicheskikh Soednenii*. 1988; 9:1232.
9. a el-Sabbagh OI, Rady HM. *Eur J Med Chem*. 2009; 44:3680. [PubMed: 19423201] b Tu SJ, Zhang Y, Jia RH, Jiang B, Zahang YJ, Ji SJ. *Tetrahedron Letters*. 2006; 47:6521.

Scheme 1.

Variation of the aldehyde in the Hantzsch reaction to expand the diversity of the dihydropyridine collection.

Scheme 2.
Introduction of a thioester into the dihydropyridines.

Scheme 3.
Substitutions of the amine in the dihydropyridine.

Scheme 4.

Substitutions of 1,3-dicarbonyls to add diversity to the dihydropyridine scaffold.

entry	compound	R ¹	R ²	R ⁴	yield
1	11a	2,4-Cl-C ₆ H ₃ -	H-		81%
2	11b	2,4-Cl-C ₆ H ₃ -	H-		82%
3	11c	2,4-Cl-C ₆ H ₃ -	H-		76%
4	11d	2,4-Cl-C ₆ H ₃ -			69%
5	11e	2,4-Cl-C ₆ H ₃ -			82%
6	11f	2-Naphthyl	H-		71%
7	11g	4-Br-C ₆ H ₄ -	H-		84%
8	11h	3-F-C ₆ H ₄ -	H-		82%
9	11i	4-(2-pyridyl)-Ph-	H-		79%
10	11j	CH ₃ -	H-		71%
11	11k	CH ₃ CH ₂ (CH ₃)CH-	H-		74%

Scheme 5.

Multiple components of the Hantzsch reaction were simultaneously exchanged to created dihydropyridines with increased diversity.

Fig. 1.

Screening results for the dihydropyridine collection against cellular tau. (A) IMR32 cells were treated for 24 hrs with 100 μM compound, followed by Western blots for total tau. Quantification of these blots are shown versus a vehicle control (1% DMSO). Also shown are two positive controls, methylene blue (MB) and 17-AAG. Arbitrary activity cut-offs are shown at $\pm 25\%$ (dotted line). Inactive compounds are shown as open symbols. Active compounds are shown in solid symbols and are labeled. *Toxic compounds. (B) Dose response analysis of the promising compound **11g**. (C) Testing of the enantiomers of **11g**. The *S* enantiomer (open symbols) had activity while the *R* enantiomer (closed symbols) was inactive. Results are the average of triplicates and the error bars are SEM.